These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 12912939)
1. Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Faridi J; Wang L; Endemann G; Roth RA Clin Cancer Res; 2003 Aug; 9(8):2933-9. PubMed ID: 12912939 [TBL] [Abstract][Full Text] [Related]
2. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. Osipo C; Gajdos C; Cheng D; Jordan VC J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267 [TBL] [Abstract][Full Text] [Related]
3. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Lykkesfeldt AE; Madsen MW; Briand P Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641 [TBL] [Abstract][Full Text] [Related]
5. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors. McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540 [TBL] [Abstract][Full Text] [Related]
6. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234 [TBL] [Abstract][Full Text] [Related]
7. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Stoica GE; Franke TF; Moroni M; Mueller S; Morgan E; Iann MC; Winder AD; Reiter R; Wellstein A; Martin MB; Stoica A Oncogene; 2003 Sep; 22(39):7998-8011. PubMed ID: 12970748 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. Osborne CK; Coronado-Heinsohn EB; Hilsenbeck SG; McCue BL; Wakeling AE; McClelland RA; Manning DL; Nicholson RI J Natl Cancer Inst; 1995 May; 87(10):746-50. PubMed ID: 7563152 [TBL] [Abstract][Full Text] [Related]
9. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice. Lee ES; Schafer JM; Yao K; England G; O'Regan RM; De Los Reyes A; Jordan VC Clin Cancer Res; 2000 Dec; 6(12):4893-9. PubMed ID: 11156249 [TBL] [Abstract][Full Text] [Related]
10. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Chisamore MJ; Ahmed Y; Bentrem DJ; Jordan VC; Tonetti DA Clin Cancer Res; 2001 Oct; 7(10):3156-65. PubMed ID: 11595710 [TBL] [Abstract][Full Text] [Related]
11. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats. Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711 [TBL] [Abstract][Full Text] [Related]
12. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. BrĂ¼nner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017 [TBL] [Abstract][Full Text] [Related]
13. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929 [TBL] [Abstract][Full Text] [Related]
14. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749 [TBL] [Abstract][Full Text] [Related]
15. Akt-induced tamoxifen resistance is associated with altered FKHR regulation. Silva J; Cavazos DA; Donzis E; Friedrichs WE; Marciniak R; deGraffenried LA Cancer Invest; 2007; 25(7):569-73. PubMed ID: 17952739 [TBL] [Abstract][Full Text] [Related]
16. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682 [TBL] [Abstract][Full Text] [Related]
17. Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells. Zhang L; Kharbanda S; Hanfelt J; Kern FG Cancer Res; 1998 Jan; 58(2):352-61. PubMed ID: 9443417 [TBL] [Abstract][Full Text] [Related]
18. A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro. Kurebayashi J; Otsuki T; Yamamoto S; Kurosumi M; Nakata T; Akinaga S; Sonoo H Oncology; 1998 Dec; 55 Suppl 1():23-34. PubMed ID: 9852399 [TBL] [Abstract][Full Text] [Related]
19. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976 [TBL] [Abstract][Full Text] [Related]
20. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]